The biggest thing that stood out to me was the large (56%) increase in Opthamology. This category has risen 43% in last 6 months. Not sure what is driving that. Good to see some increases in all categories.

Otherwise good cost management and perhaps some price increases (?) drove the financials once again as cash increased nicely.

Does not look like any large new R&D efforts underway as those expenses fell. Not much to complain about, but someday would like to see some break out new products through organic development or acquisition.

sw